Alumis Loses Half Its Value as Lupus Trial Misses

Alumis said its phase 2b trial of the TYK2 inhibitor envudeucitinib in lupus missed both primary and secondary endpoints, yet the company will advance the drug into phase 3 on the strength of a prespecified patient subgroup; ALMS fell 53.74% to 10.09 by 13:50 GMT on Sept. 1, 2026.

Alumis (ALMS) lost more than half its market value on Tuesday after the biotech disclosed that a mid-stage trial of its TYK2 inhibitor envudeucitinib in systemic lupus failed to hit its primary endpoint or its secondary endpoints. The shares were quoted at 10.09 as of 13:50 GMT on Sept. 1, 2026, down 53.74% from the previous close of 21.81, with an intraday range of 9.55 to 15.63.

The unusual part is what the company said next. Rather than shelving the program in lupus, Alumis intends to push envudeucitinib into phase 3 in the same disease, citing evidence of efficacy in a prespecified subgroup of patients as the basis for that decision. The Fierce Biotech report framed the readout as a crushing miss paired with a stubborn commitment to the indication.

Why a failed primary endpoint still leaves a program alive

A phase 2b trial is the dose-finding, hypothesis-sharpening study that is supposed to tell a company whether a drug works well enough, and in whom, to justify the far larger expense of phase 3. The primary endpoint is the single pre-agreed measure of success. Missing it, and missing the secondary endpoints behind it, is the clearest signal a mid-stage trial can send that the overall population studied did not benefit measurably more than placebo.

Subgroup analyses are the standard fallback. Because they were prespecified — written into the statistical plan before the data were unblinded — they carry more weight than a post-hoc trawl through the numbers. But prespecification does not solve the underlying arithmetic problem: subgroups are smaller than the full trial population, so the confidence intervals are wider and the chance that an apparent benefit is noise is higher. Regulators generally treat a subgroup finding in a failed trial as a hypothesis to be tested, not as evidence of efficacy. That is exactly the posture Alumis is adopting by taking it into phase 3.

Lupus is also a notoriously unforgiving indication. Systemic lupus erythematosus produces heterogeneous symptoms across organ systems, response measures are composite and partly subjective, and placebo response rates have historically been high enough to swallow real drug effects. The disease has buried more mid-stage programs than almost any other autoimmune target. A miss in lupus therefore says less about a molecule's biology than a miss in a cleaner indication would — which is part of the argument for continuing.

The TYK2 field is crowded and the bar has moved

TYK2 is a member of the Janus kinase family. Inhibiting it damps down signaling from interferons and interleukins central to autoimmune inflammation, and selective TYK2 blockade has been pitched as a way to get JAK-like efficacy without the safety warnings that have dogged broader JAK inhibitors. The mechanism has already been validated commercially in psoriasis, which means any newcomer is being judged against an approved comparator rather than against placebo alone in the minds of investors.

That matters for how the market read Tuesday's news. A selective TYK2 inhibitor that clears the bar in lupus would be entering an area with genuine unmet need and few oral options. One that needs a subgroup argument to get there is a different asset entirely: later, more expensive, and with a narrower eventual label if it works at all. A drop of 53.74% in a single session is the market pricing a shift from broad-population opportunity to a restricted, higher-risk one.

Cash, timelines and the cost of a phase 3

Phase 3 in lupus is among the most capital-intensive undertakings in autoimmune development. Enrollment is slow because eligibility criteria are tight, trials typically run for a year or more of treatment, and the composite endpoints require large numbers of patients to demonstrate separation from placebo. For a company whose equity value has just halved, the financing question becomes the dominant one. Raising capital after a failed readout means selling more shares at a much lower price to fund the same study — dilution that compounds the clinical risk.

Alumis has not, in the information available, put a start date, patient count or budget on the planned phase 3, and investors should not assume one. Those are the specifics that will determine whether the decision to continue reads as conviction or as a program looking for a reason to exist. The questions worth tracking:

• The subgroup definition. How was it drawn — by biomarker, by baseline disease activity, by background medication? A biologically coherent subgroup is a far better foundation than a demographic slice.
• Regulatory alignment. Whether the FDA agrees the subgroup supports a registrational design, and on what endpoint.
• Funding. Whether the phase 3 is financed from existing resources, a raise, or a partner willing to share the cost.
• The rest of the pipeline. Whether envudeucitinib's other indications absorb capital that would otherwise go to lupus, or vice versa.

A single-stock collapse against a soft tape

The move stands out sharply against the broader market, which was mildly lower rather than distressed. As of 13:50 GMT on Sept. 1, 2026, the S&P 500 tracker SPY was at $762.23, down 0.63% from a prior close of $767.05. The Nasdaq 100 proxy QQQ was at $708.15, off 1.20% from $716.76, and the Dow tracker DIA sat at $529.13, down 0.46% from $531.57. None of those moves explains a decline of more than fifty percent; this was entirely company-specific news.

That asymmetry is the defining feature of clinical-stage biotech as an asset class. A single unblinding can reprice a company's entire equity in minutes, because the value of a pre-revenue developer is a probability-weighted bet on a small number of binary outcomes. When the probability attached to the largest of those outcomes falls, so does everything.

What Alumis retains is a mechanism with commercial validation elsewhere, a prespecified signal it can take to regulators, and the option to continue. What it has lost is the benefit of the doubt. Until the company details the subgroup, the trial design and the money behind it, the phase 3 announcement is a statement of intent rather than a plan the market is willing to underwrite — and Tuesday's price tells you which of those two the shareholders think they own.

Key facts

• ALMS price: 10.09, -53.74% as of 13:50 GMT, Sept. 1, 2026
• Previous close: 21.81; day range 9.55–15.63
• Trial outcome: Phase 2b lupus study missed primary and secondary endpoints
• Next step: Phase 3 in lupus, based on a prespecified subgroup

Frequently asked questions

What happened in Alumis' phase 2b lupus trial?

Alumis reported that its mid-stage trial of envudeucitinib, a TYK2 inhibitor, in systemic lupus failed to meet its primary endpoint and also missed its secondary endpoints. Despite the miss across the overall study population, the company said it identified evidence of efficacy in a prespecified subgroup of patients and will advance the drug into phase 3 testing in the same disease.

How far did Alumis stock fall?

Shares of Alumis were quoted at 10.09 as of the last trade at 13:50 GMT on Sept. 1, 2026, a decline of 53.74% from the previous close of 21.81. The intraday range ran from 9.55 to 15.63, indicating heavy volatility through the session as investors repriced the company after the trial disclosure.

What is a TYK2 inhibitor?

TYK2 is an enzyme in the Janus kinase family that helps relay inflammatory signals from interferons and certain interleukins inside immune cells. Selectively blocking it is intended to reduce autoimmune inflammation while avoiding the broader safety warnings associated with less selective JAK inhibitors. The mechanism has already been commercially validated in psoriasis.

Why continue to phase 3 after a failed trial?

Because the subgroup finding was prespecified — written into the statistical plan before the data were unblinded — it carries more weight than an after-the-fact analysis. Companies sometimes use such signals to design a narrower phase 3 in a better-defined patient population. Regulators typically treat a subgroup result from a failed trial as a hypothesis needing confirmation, not proof of efficacy.

Why is lupus considered a difficult indication?

Systemic lupus erythematosus affects multiple organ systems with widely varying symptoms, and response is measured using composite scores that include subjective components. Placebo response rates in lupus trials have historically been high, which can mask a genuine drug effect. Many mid-stage lupus programs across the industry have failed for these reasons rather than because the underlying biology was wrong.

How did the broader market perform that day?

Major index trackers were modestly lower as of 13:50 GMT on Sept. 1, 2026. SPY, tracking the S&P 500, was at $762.23, down 0.63%. The Nasdaq 100 proxy QQQ was at $708.15, down 1.20%, and Dow tracker DIA was at $529.13, down 0.46%. None of those moves accounts for Alumis' decline, which was driven entirely by its own trial news.

Sources

• Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor — Fierce Biotech

Photo: Tima Miroshnichenko · Pexels Licence — source